Papers in BMJ Oncology
Page 3 · newest first
- Patina of precision: risk models for lung cancer screening eligibilityBMJ Oncology · 2025
- Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinomaBMJ Oncology · 2025
- Six-year performance of risk-based selection for lung cancer screening in the Manchester Lung Health Check cohortBMJ Oncology · 2024
- Cancer incidence and competing mortality risk following 15 presenting symptoms in primary care: a population-based cohort study using electronic healthcare recordsBMJ Oncology · 2024
- From prediction to practice: mitigating bias and data shift in machine-learning models for chemotherapy-induced organ dysfunction across unseen cancersBMJ Oncology · 2024
- Which patients with symptoms should be referred urgently for investigation of suspected cancer?BMJ Oncology · 2024
- Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastasesBMJ Oncology · 2024
- Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and moreBMJ Oncology · 2024
- Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old menBMJ Oncology · 2024
- Circulating tumour cell clusters: isolation, biological significance and therapeutic implicationsBMJ Oncology · 2024
- Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitorsBMJ Oncology · 2024
- Cancer burden across the South Asian Association for Regional Cooperation in 2022BMJ Oncology · 2024
- UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE studyBMJ Oncology · 2024
- Integrated multiplex analysis of cell death regulators in stage II colorectal cancer suggests patients with ‘persister’ cell profiles fail to benefit from adjuvant chemotherapyBMJ Oncology · 2024
- Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancerBMJ Oncology · 2024
- Under-representation of older Indian persons with cancer in clinical trialsBMJ Oncology · 2024
- Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignanciesBMJ Oncology · 2024
- Vitamin B6 status and chronic chemotherapy-induced peripheral neuropathy: a prospective cohort study among patients with non-metastatic colorectal cancer receiving oxaliplatin-based chemotherapyBMJ Oncology · 2024
- Prospective comparative study of quality of life in patients with bladder cancer undergoing cystectomy with ileal conduit or bladder preservationBMJ Oncology · 2024
- As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022BMJ Oncology · 2024
- Preconsultation compassion video to reduce anxiety among patients referred to a cancer centre: a randomised control trialBMJ Oncology · 2024
- Choosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancerBMJ Oncology · 2024
- Deciphering chemotherapy resistance: a novel apoptosis protein profile analysis in stage II colorectal cancerBMJ Oncology · 2024
- Recall of ibrutinib and issues with therapeutic approvalBMJ Oncology · 2024
- Determining fracture risk in patients exposed to immune checkpoint inhibitors: the time is nowBMJ Oncology · 2024
- Do shortcuts leave older patients short changed? The UK TOASTIE studyBMJ Oncology · 2024
- Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?BMJ Oncology · 2024
- Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncologyBMJ Oncology · 2024
- Novel machine learning algorithm in risk prediction model for pan-cancer risk: application in a large prospective cohortBMJ Oncology · 2024
- Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerBMJ Oncology · 2024
- Surgical management of skull base chordomas and chondrosarcomas: insights from a national cohort studyBMJ Oncology · 2024
- Research priorities to improve cancer care for people with intellectual disabilities across the cancer continuumBMJ Oncology · 2024
- Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic reviewBMJ Oncology · 2024
- Potential of neutrophil-to-eosinophil ratio as a new prognostic tool for patients with advanced renal cell carcinoma receiving first-line immuno-oncology combinationsBMJ Oncology · 2024
- Does the regional use of intensive chemotherapy impact the outcome of adults with AML?BMJ Oncology · 2024
- Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trialBMJ Oncology · 2024
- Addressing the hidden toxicities of cancer: a call to action for clinicians, researchers and clinical trialistsBMJ Oncology · 2024
- First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumoursBMJ Oncology · 2024
- Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapyBMJ Oncology · 2024
- Patterns of cytotoxic T-cell densities in immunogenic endometrial cancers reveal a potential mechanism for differences in immunotherapy efficacyBMJ Oncology · 2024
- Defining national research priorities for prostate cancer in Zambia: using the Delphi process for comprehensive cancer policy setting in sub-Saharan AfricaBMJ Oncology · 2024
- Blood-based DNA methylation markers for lung cancer predictionBMJ Oncology · 2024
- Prospective evaluation of artificial intelligence (AI) applications for use in cancer pathways following diagnosis: a systematic reviewBMJ Oncology · 2024
- Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date reviewBMJ Oncology · 2024
- Does the evidence exist for the deployment of AI in cancer therapies?BMJ Oncology · 2024
- Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trialsBMJ Oncology · 2024
- Sex and authorship in global cancer researchBMJ Oncology · 2024
- Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapyBMJ Oncology · 2024
- Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysisBMJ Oncology · 2024
- Tale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysisBMJ Oncology · 2024